Kornimate/medical-research-clean huggingface dataset:
effects of multimodal analgesia on serum mcp-1, bdnf, and mirna-124 in hysterectomy surgery

Conditions: Inflammation; Inflammatory Response; Acute Pain; Chronic Pain

Summary: the inflammatory process is the main mechanism in the occurrence of acute postoperative pain. it is also the main risk for the development of acute pain into persistent pain. inflammation occurs in the process of peripheral sensitization and central sensitization with various inflammatory mediators. postoperatively, there will be proliferation and activation of microglia and astrocytes which will then activate inflammatory receptors and signaling cascades of neurotransmitters, cytokines, and chemokines. there has been a lot of clinical research evidence that multimodal analgesia can adequately treat acute pain and can prevent the development of acute postoperative pain into persistent pain and chronic postoperative pain, but the molecular mechanisms are not fully understood.


Eligibility criteria:
inclusion criteria: * scheduled for elective hysterectomy * american society of anesthesiologists (asa) physical status 1 to 3 exclusion criteria: * allergy to studied drugs * history of chronic pain * history of hepatitis, depression, peptic ulcer, or acute myocardial infarction * receive intraoperative massive blood transfusion * prolonged coagulation * body mass index \>35 kg/m2 * patients with neurological deficits * taking anti-platelet medications
effects of acupuncture stimulation on systemic inflammation

Conditions: Nonsmall Cell Lung Cancer

Summary: 60 asa physical status i or ii patients, aged 18-75 years old , scheduled for elective video-assisted thoracoscopic lobectomy surgery,will be randomized into 2 groups,with 30 patients in each group: 1. control group and 2. treatment group. patients in treatment group will receive transcutaneous electrical acupoint stimulation(teas) during the surgery and at 6h and 24h after surgery. patients in the control group received only tiva general anesthesia and sham electrical stimulation. serum from patients of both groups will be collected at before surgery, 1h and 25h after surgery, respectively. serum levels of tnf-alpha, il-1 beta, cxcl8, ifn gamma and il-4 at different time points will be measured and compared between the two groups.

60 asa physical status i or ii patients, aged 18-75 years old , scheduled for elective video-assisted thoracoscopic lobectomy surgery,will be randomized into 2 groups,with 30 patients in each group: 1. control group, who will receive total intravenous anesthesia(tiva) and sham stimulation; and 2. treatment group, who will receive (tiva) and transcutaneous electrical acupoint stimulation(teas). since 30 min before induction of anesthesia, patients in treatment group will be stimulated at the 4 acupoints , houxi、zhigou、neiguan and hegu on both sides by han's acupoint nerve stimulator(hans) until the end of the operation. at 6h and 24h after surgery, patients in treatment group will receive teas again, for 30 min each time.the frequency was 2/100hz,the stimulate intensity was the maximum current that could be tolerated when the patients were awake.the control group received only tiva general anesthesia and sham electrical stimulation.serum from patients of both groups will be collected at before surgery, 1h and 25h after surgery, respectively and serum levels of tnf-alpha, il-1 beta, cxcl8, ifn gamma and il-4 at different time points will be measured. the primary outcome measures are serum tnf-alpha and il-1 beta levels at 25h after surgery. the secondary outcome measures include serum levels of tnf-alpha, il-1 beta, cxcl8, th1/th2 ratio (by calculating ifn gamma/il-4) at 1h post surgery and serum levels of cxcl8, th1/th2 ratio at 25h post surgery.

Eligibility criteria:
inclusion criteria: * patients diagnosed non-small cell lung carcinoma (nsclc) and will have elective video-assisted thoracoscopic lobectomy surgery * asa grade 1-2 * bmi between 18 to 31 kg/m2 exclusion criteria: * with a history of thoracic surgery * unwilling to receive transcutaneous electrical acupoint stimulation * bmi ≥ 32 kg/m2 * infection or scars at the acupoints * periphery nerve injury at the upper or lower limbs * severe liver, renal, brain or lung disease * drug abuse * patients who cannot coordinate with investigators, such as dysphasia，severe infectious disease and disturbance of consciousness * patients participating other trials
efficiency of speech and language intervention on achievement of children with developmental language disorder

Conditions: Language Development Disorders; Speech and Language Disorder; Therapy

Summary: children with developmental language disorder (dld) have many linguistic difficulties in syntax, lexicon, morphology and phonology. frequently, they also present co-occurrent (or comorbidities) impairments which further impaired school learning. thus, they have poor academic outcomes and many of these children have been maintained at least one time in a classroom, sometime more. the purpose of this project is to determine which modalities of speech and language therapy are the more efficient on academic outcomes of children with dld. the main modalities that will be studied are the duration of speech and language intervention, the age at which begins the intervention and the intensity (number of intervention sessions per week).


Eligibility criteria:
inclusion criteria: * patients have been diagnosed in the university hospital of amiens-picardie with a developmental language disorder * patients must be aged 12 or older, * patients must be agreed answering the questionnaire exclusion criteria: * children with a neurological pathology or handicap as epilepsy, cerebral palsy, sequelae of severe brain injury (traumatic or ischemic or inflammatory...) * patients with a severe mental retardation * patients with autism * patients with bipolar illness * patients with psychosis

Keywords: language development disorders speech and language disorder academic outcomes
effects of aerobic dance based exercise program after surgery in obeses awating bariatric surgery

Conditions: Morbid Obesity; Bariatric Surgery Candidate; Exercise; Obesity

Summary: in this study, our primary aim is; investigate the effect of aerobic dance based exercise program on lower extremity functions (walking, stair stroke climbing, etc.) in obese individuals awaiting bariatric surgery.

in this study, our primary aim is; investigate the effect of aerobic dance based exercise program on lower extremity functions (walking, stair stroke climbing, etc.) in obese individuals awaiting bariatric surgery. . our secondary aim is to provide the individual with exercise habits and increase the level of physical activity in daily life with the exercise program planned according to the needs of the individual.

Eligibility criteria:
inclusion criteria: * individuals aged between 18-65 * body mass index ≥40 or ≥35 with concomitant diseases * no surgical operation in the last 6 months exclusion criteria: * musculoskeletal disorders or systemic diseases that may prevent exercise * the presence of psychiatric or neurological disease affecting cooperation and cognitive functions * presence of acute pain * heart pain * presence of previous myocardial infarction, subjective heart failure, uncontrolled diabetes and hypertension * regular exercise for 6 months

Keywords: bariatric surgey morbid obesity aerobic exercise lower extremity functions
study to look at how effective briviact is as add-on treatment for patients with epilepsy with partial onset seizures

Conditions: Epilepsy With POS With or Without Secondary Generalization

Summary: study is the first study after commercialization of brivaracetam. it is designed to collect real world information on the effectiveness of brivaracetam in patients with partial onset seizure epislepsy who are treated in standard clinical practice.

ep0077 is a 12 months, multicenter, noninterventional study (nis) conducted at specialized sites in approximately 10 european countries. patients will be treated according to usual medical diagnostic procedures and therapy; commercially available brivaracetam will be prescribed according to normal clinical practice and the current summary of product characteristics (smpc) in europe for brivaracetam (brv). the prescription of brv is clearly separated from the decision to include the patient in the study. no additional diagnostic or monitoring procedures are applied to the patients. the primary objective of this study is to determine brv retention over a 12 month period as a measure of effectiveness in a real world setting. the secondary objective of this study is to assess seizure control with brv treatment.

Eligibility criteria:
inclusion criteria: * patient has never been treated with brivaracetam (brv) prior to enrollment in this non-interventional study (nis) * the decision by the treating physician to prescribe brv is made independently of the participation in the nis * patient is a male or female ≥16 years of age * patient has a clinical diagnosis of epilepsy with partial-onset seizures pos with or without secondary generalization * patient uses an epilepsy/seizure diary. exclusion criteria: no specific exclusion criteria

Keywords: non-interventional (nis) epilepsy partial onset seizures (pos) add-on therapy
exercise for patients with renal cell cancer receiving sunitinib

Conditions: Renal Cell Carcinoma

Summary: in this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with sunitinib.


Eligibility criteria:
inclusion criteria: * 18 to 75 years * understanding of written german * treatment with sunitinib * ability to walk exclusion criteria: * cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise * bmi \ 30

Keywords: cancer renal cell carcinoma fatigue exercise
a clinical study intended to compare treatment with voriconazole to treatment with amphotericin followed by fluconazole in patients with candidemia, a serious fungus infection of the blood.

Conditions: Candidiasis

Summary: this is a study to investigate the safety and efficacy of voriconazole for the treatment of candidemia in critically ill non-neutropenic patients


Eligibility criteria:
inclusion criteria: * patients with candidemia exclusion criteria: * neutropenia
does clomiphene citrate used for induction of ovulation effect levels of amh and inhibin b

Conditions: Infertility

Summary: 100mg clomiphene citrate used for ovulation induction. the investigators take blood sample at 3 and 10 days of menstruation and count amh and inhibin b.

100mg clomiphene citrate used for ovulation induction. the investigators take blood sample at 3 and 10 days of menstruation. amh and inhibit b level will be measured in serum. we want to search relation of amh, inhibin b and ovulation induction.

Eligibility criteria:
inclusion criteria: * infertility treatment exclusion criteria: * previous ovarian surgery * single functioning ovary

Keywords: clomiphene citrate amh inhibin b
adaptation of the one-session cbt protocol for prevention of mental illness for brazilian portuguese

Conditions: Mental Disorder; CBT

Summary: 1. recruitment of medicine students of federal university. 2. psychiatric interview (mini) and sclaes application. 3. protocol of cbt 4. scales and mini will be applied at the times of 7, 30 and 90 days after the end of the therapy. 5. statistical analysis


Eligibility criteria:
inclusion criteria: * be medical student * be over 18 years of age * agree to the term of free and informed consent. exclusion criteria: * students with psychotic illness, severe depression, manic episode or acute psychiatric risk.
sleep-disordered breathing in patients with severe valvular regurgitation undergoing clip procedure

Conditions: Sleep Disordered Breathing; Valvular Regurgitation

Summary: in a prospective observational study, the investigators investigate the prevalence of sleep disordered breathing in patients with severe valvular regurgitation and the effect of using the minimal invasive clip technique on sleep disordered breathing.

the purpose of this study is to analyze the prevalance of sleep disordered breathing in patients with severe valvular regurgitation and the impact of a therapy with the minimal-invasive clip technique. therefore, the investigators want to include consecutive patients with unknown sleep-associated respiratory distress syndrome and, in addition, as a study-specific achievement, the investigators want to obtain the quality of life and specific symptoms of the patients by using established questionnaires. after three month of post-interventional care, the patients will get a post-interventional check-up in our cardiological outpatient clinic, where the course of sleep-associated respiratory distress syndrome and the actual quality of life and specific symptoms will be documented by using a cardiorespiratory polygraphy and the same questionnaires. the entire hospital stay, including possible post-interventional complications, will be documented for this study from the patients' medical records. the routine examinations (laboratory values, ecg, 6-minute walk test, pulmonary function examinations, spiroergometry, transthoracic / -oesophageal echocardiography, etc.) shall also be recorded in the database of this study. the plan is to include 100 evaluable patients with complete follow-up and the associated test results. for this purpose, a screening of 150 patients is expected to be required.

Eligibility criteria:
inclusion criteria: * patients with severe valvular regurgitation and currently unknown sleep disorder breathing who will be treated with a minimal invasive clip technique exclusion criteria: * patients with more then one valvular disease which requires treatment * patients with complex congenital heart disease * pregnant women

Keywords: minimally invasive surgery clip procedure
0.05 mg versus 0.1 mg spinal morphine for reducing morphine requirement after vaginal hysterectomy

Conditions: Pain

Summary: this study aims to compare the effect of spinal morphine between the dose 0.05 mg and 0.1 mg on the amount of morphine during the first 24 hours postoperative.


Eligibility criteria:
inclusion criteria: * female asa 1-3 * undergoing vaginal hysterectomy with/without anterior and posterior vaginoplasty * can operate pca device exclusion criteria: * history of allergy to the study drugs * history of bleeding tendency * history of infection at the back * patient refuse to have spinal anesthesia * history of cad or cvd

Keywords: spinal morphine vaginal hysterectomy
evaluate the effects of the drug (sb-656933-aaa) on the body after a single dose in subjects who have inhaled ozone

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: a study to evaluate the effect of sb-656933-aaa on the body after a single dose in subjects who have been challenged with ozone.


Eligibility criteria:
inclusion criteria: * healthy subjects between 18-50 years. * females should be of non-child bearing potential. * non-smoking for at least 12 months. * normal lung function. * subjects should be able to produce acceptable sputum samples. exclusion criteria: * any serious medical condition. * hepatitis b or c and/or hiv positive. * currently on regular medication except paracetamol. * body mass index \ 30.

Keywords: sb-656933-aaa, ozone challenge single dose,
drug nephrotoxicity amelioration by n-acetylcysteine

Conditions: Drug-Induced Nephropathy

Summary: when treating individuals with febrile neutropenia, amphotericin b (amb-d) is one of the most effective treatments against often fatal systemic fungal infections.nephrotoxicity from amphotericin b can develop with an incidence of up to 80.this emphasizes the value of nephroprotectant agent use.because of n-acetylcysteine's antioxidant, antiapoptotic, vasodilator properties and its therapeutic effects on contrast nephropathy. acetylcysteine's impact on amphotericin b-induced nephrotoxicity in cancer patients is assessed.

severe fungal infections continue to be a significant source of morbidity and mortality in haematology units despite recent therapeutic advancements. the first anti-fungal medication that was successful against systemic mycoses was characterised as the traditional amphotericin b in the middle of the 1950s.amb remains the treatment of choice for many serious fungal infections in vulnerable hosts owing to its excellent spectrum of activity and its low resistance rates. to date, it continues to be the agent with the widest spectrum of action and the lowest resistance potential of any known antifungal agent.in spite of clinical effectiveness, amb treatment is associated with a range of acute and chronic adverse reactions . nephrotoxicity and consequent electrolytes imbalances have been demonstrated as the most clinically significant adverse reaction of amb that can restrict its clinical utility. up to 80 % of amb recipients during the first two weeks of treatment may develop some degree of reversible kidney injury . in addition, nearly 15 % of these patients may require dialysis which can lead to prolongation of hospital stay, increased total treatment costs, and mortality . n-acetylcysteine, a drug with vasodilating, antiapoptotic, and anti-oxidant features, has been found to diminish the nephrotoxicity of cisplatin , cyclosporine and gentamicin . the results of two experimental studies in rats have suggested that n-acetylcysteine can mitigate gfr reduction as well as renal tubular apoptosis caused by amb .

Eligibility criteria:
inclusion criteria: * age more than 18 years. * patients who have indication for systemic (injection) for conventional amphotericin at least 7 days. exclusion criteria: * documented acute kidney injury defined by an increase in serum creatinine ‡ 0.3 mg/dl within 48 h, or an increase in serum creatinine by ‡ 1.5 times baseline within the prior 7 days, or urine volume \<0.5 ml/kg/h for 6 h * documented chronic kidney disease (clearance creatinine below 60 ml/min/1.73 m2 calculated by the abbreviated modification of diet in renal disease equation), history of peritoneal or hemodialysis for \> 3 months * sepsis * severe hemorrhage(blood loss \> 3 litres) * patient with cardiac or chronic liver disease history of receiving amb by any administration route within the recent 14 days known allergy to either amphotericin b or n-acetylcysteine. * receiving any formulation of nac within the last week. * unable to tolerate oral intake.
therapeutic drug monitoring for biological therapy in pediatric inflammatory bowel disease

Conditions: Ulcerative Colitis (UC); IBD-unclassified (IBD-U)

Summary: inflammatory bowel diseases (ibd), which include crohn's disease (cd), ulcerative colitis (uc), and the unclassified form referred to as indeterminate colitis, are most commonly diagnosed during adolescence and early adulthood. in recent decades, an increasing incidence of ibd has been observed in this age group. a wide range of immunomodulatory agents, from corticosteroids to monoclonal antibodies, are now available for the treatment of ibd. these antibodies, known as biologics, target, for example, tumor necrosis factor-alpha (tnf-α; e.g., infliximab and adalimumab), integrin α4β7 (vedolizumab), or interleukin-12/23 (ustekinumab). while infliximab and adalimumab are approved for pediatric use in cd and uc, vedolizumab is only approved for moderate-to-severe uc from the age of 16, and ustekinumab is not approved for pediatric use at all. nevertheless, vedolizumab and ustekinumab are frequently used off-label in cases of treatment failure with approved therapies, as efficacy has been demonstrated in adult ibd patients, and since 2015, increasing pediatric literature has emerged on their use. to facilitate appropriate dose adjustment in pediatric clinical practice, biologic therapies can be monitored through measurement of drug trough levels. current pediatric guidelines already recommend incorporating therapeutic drug monitoring (tdm) of infliximab and adalimumab in the management of cd and uc. studies on tdm for vedolizumab and ustekinumab have so far been conducted almost exclusively in adult ibd patients, where improved treatment responses have also been demonstrated. the presented research is a prospective, non-interventional observational study involving pediatric ibd patients at multiple austrian pediatric gastroenterology centers. the study duration is five years. the aim is to include at least 40 patients receiving induction and maintenance therapy with infliximab or adalimumab, and 20 patients treated with vedolizumab or ustekinumab during both treatment phases. the primary objective is to gain a better understanding of the pharmacokinetic dynamics of these biologics and the associated treatment response in pediatric settings. data will be collected exclusively from routine clinical assessments. no additional study-related visits or interventions are planned.


Eligibility criteria:
inclusion criteria: * pediatric patients with an inflammatory bowel disease (crohn's disease, ulcerative colitis, and ibd-unclassified) being under 18 years of age * treatment with infliximab, adalimumab, vedolizumab, or ustekinumab during induction or maintenance phase exclusion criteria: -- patients with primary (congenital) immunodeficiency

Keywords: ibd pediatric biologicals infliximab adalimumab vedolizumab ustekinumab
evaluation of efficacy and safety of e004 in children with asthma

Conditions: Asthma

Summary: this is a multi-center, randomized, double-blinded, placebo-controlled, parallel, 4-week study in 60 pediatric patients (4-11 years old) with asthma, comparing e004 with placebo hfa-mdi in pediatric patients who are 4-11 years of age with asthma.


Eligibility criteria:
inclusion criteria: * generally healthy male, and premenarchal female, children aged 4 - 11 years upon screening. * with documented asthma, requiring inhaled epinephrine or beta2-agonist treatment, with or without concurrent anti-inflammatory therapies for at least 6-months prior to screening. * being capable of performing spirometry for fev1 * satisfying criteria of asthma * can tolerate withholding treatment with inhaled bronchodilators and other allowed medications for the minimum washout periods * demonstrating a screening baseline fev1 that is 50 - 90% of polgar predicted normal value. * demonstrating an airway reversibility, * demonstrating satisfactory techniques in the use of a metered-dose inhaler (mdis) and a hand held peak expiratory flow meter, after training. * has been properly consented to participate in this study. exclusion criteria: * any current or past medical conditions that, per investigator discretion, might significantly affect pharmacodynamic responses to the study drugs * concurrent clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, or malignant diseases. * known intolerance or hypersensitivity to any component of the study drugs * recent infection of the respiratory tract * use of prohibited medications * having been on other investigational drug/device studies in the last 30 days prior to screening.

Keywords: mild bronchial asthma